We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ASPCQ Acerus Pharmaceuticals Corporation (PK)

0.00 (0.00%)
Apr 11 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 0.00
Bid Price
Ask Price
News -
Share Name Share Symbol Market Stock Type
Acerus Pharmaceuticals Corporation (PK) ASPCQ OTCMarkets Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.21988 19:00:00
Open Price Low Price High Price Close Price Previous Close
0.21988 0.21988
Trades Shares Traded Average Volume
0 0.00 -
Last Trade Type Quantity Price Currency
- 0 US$ 0.21988 USD

Acerus Pharmaceuticals Corporation (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 1.69M 7.71M 662.94k - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Acerus Pharmaceuticals (PK) News

Real-Time news about Acerus Pharmaceuticals Corporation (PK) (OTCMarkets): 0 recent articles
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ASPCQ Message Board. Create One! See More Posts on ASPCQ Message Board See More Message Board Posts

Historical ASPCQ Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.
3 Years0.
5 Years0.

Acerus Pharmaceuticals (PK) Description

Acerus is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience. Founded in 2008, Acerus has quickly grown into a fully integrated company with expertise in all stages of the pharmaceutical product lifecycle, and focus in the therapeutic areas of Men's Health (Urology) and Women's Health (Hormone Replacement Therapy). Acerus has global rights to NATESTO, a product utilizing our licensed nasal gel technology, is the first and only testosterone nasal gel approved in Canada, and the United States for replacement therapy in adult males diagnosed with hypogonadism. Acerus operates from a Mississauga-based office, and is listed on the Toronto Stock Exchange (TSX:ASP)

Your Recent History

Delayed Upgrade Clock